Navigation Links
GSK and Adolor Announce Preliminary Results from Phase 3 Safety,Study of Alvimopan (Entereg/Entrareg)

Entereg studies, changing regulatory requirements, the risk that the FDA may not agree with Adolor's and GSK's analyses of the Entereg studies (including Study 014) and may evaluate the results of these studies by different methods or conclude that the results from the studies, whether or not statistically significant, do not support safety, efficacy, a favorable risk/benefit profile, or there were human errors in the conduct of the studies, or otherwise; adverse safety findings in any Entereg studies; the risk that regulatory approvals for the use of Entereg in OBD are not achieved; the risk that filing targets for regulatory submissions or user fee goal dates are not met; the risk that the results of other clinical trials of Adolor's drug product candidates, including Entereg, are not positive; the risk of product liability claims; reliance on third party manufacturers; the costs, delays and uncertainties inherent in scientific research, drug development, clinical trials and the regulatory approval process; Adolor's history of operating losses since inception and its need for additional funds to operate its business; Adolor's reliance on its collaborators, including GSK, in connection with the development and commercialization of Entereg; market acceptance of Adolor's products, if regulatory approval is achieved; competition; and securities litigation.

Further information about these and other relevant risks and uncertainties may be found in Adolor's Reports on Form 8-K, 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Adolor urges you to carefully review and consider the disclosures found in its filings which are available in the SEC EDGAR database at http://www.sec.gov and from Adolor at http://www.adolor.com. Given the uncertainties affecting pharmaceutical companies in the development stage, you are cautioned not to place undue reliance on any such forward-looking statements, any of which may turn out to be wrong due to inaccurate
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
(Date:5/5/2015)... 5, 2015 Merrimack Pharmaceuticals, Inc. (Nasdaq: ... randomized, double-blinded, placebo-controlled Phase 2 clinical trial of ... in combination with nab-paclitaxel and gemcitabine, versus nab-paclitaxel ... pancreatic cancer who have high serum levels of ... fourth leading cause of cancer death in ...
(Date:5/5/2015)... May 5, 2015   Cynosure, Inc. (Nasdaq: ... devices for aesthetic procedures and precision surgical applications worldwide, ... March 31, 2015. First-Quarter Highlights: , ... , Non-GAAP earnings of $0.15 per share; GAAP earnings ... at March 31, 2015 "Cynosure delivered 21 ...
(Date:5/5/2015)... 5, 2015  Astellas announced that two abstracts detailing ... detailing clinical data from a study of mirabegron as ... a late breaking plenary session at the 2015 annual ... 17 in New Orleans, Louisiana . ... studies designed to evaluate enzalutamide compared to bicalutamide in ...
Breaking Medicine Technology:Merrimack Pharmaceuticals Announces Initiation of a Phase 2 Front-line Clinical Trial of MM-141 in Biomarker-Selected Patients with Metastatic Pancreatic Cancer 2Merrimack Pharmaceuticals Announces Initiation of a Phase 2 Front-line Clinical Trial of MM-141 in Biomarker-Selected Patients with Metastatic Pancreatic Cancer 3Merrimack Pharmaceuticals Announces Initiation of a Phase 2 Front-line Clinical Trial of MM-141 in Biomarker-Selected Patients with Metastatic Pancreatic Cancer 4Cynosure Announces First-Quarter 2015 Results; Posts Record First-Quarter Revenue of $74.9 Million, Up 21 Percent from Prior Year 2Cynosure Announces First-Quarter 2015 Results; Posts Record First-Quarter Revenue of $74.9 Million, Up 21 Percent from Prior Year 3Cynosure Announces First-Quarter 2015 Results; Posts Record First-Quarter Revenue of $74.9 Million, Up 21 Percent from Prior Year 4Cynosure Announces First-Quarter 2015 Results; Posts Record First-Quarter Revenue of $74.9 Million, Up 21 Percent from Prior Year 5Cynosure Announces First-Quarter 2015 Results; Posts Record First-Quarter Revenue of $74.9 Million, Up 21 Percent from Prior Year 6Cynosure Announces First-Quarter 2015 Results; Posts Record First-Quarter Revenue of $74.9 Million, Up 21 Percent from Prior Year 7Cynosure Announces First-Quarter 2015 Results; Posts Record First-Quarter Revenue of $74.9 Million, Up 21 Percent from Prior Year 8Cynosure Announces First-Quarter 2015 Results; Posts Record First-Quarter Revenue of $74.9 Million, Up 21 Percent from Prior Year 9Cynosure Announces First-Quarter 2015 Results; Posts Record First-Quarter Revenue of $74.9 Million, Up 21 Percent from Prior Year 10Cynosure Announces First-Quarter 2015 Results; Posts Record First-Quarter Revenue of $74.9 Million, Up 21 Percent from Prior Year 11Astellas Announces New Data To Be Presented During Late Breaking Plenary Session At AUA Annual Meeting 2Astellas Announces New Data To Be Presented During Late Breaking Plenary Session At AUA Annual Meeting 3Astellas Announces New Data To Be Presented During Late Breaking Plenary Session At AUA Annual Meeting 4Astellas Announces New Data To Be Presented During Late Breaking Plenary Session At AUA Annual Meeting 5Astellas Announces New Data To Be Presented During Late Breaking Plenary Session At AUA Annual Meeting 6Astellas Announces New Data To Be Presented During Late Breaking Plenary Session At AUA Annual Meeting 7Astellas Announces New Data To Be Presented During Late Breaking Plenary Session At AUA Annual Meeting 8Astellas Announces New Data To Be Presented During Late Breaking Plenary Session At AUA Annual Meeting 9
(Date:5/5/2015)... York, NY (PRWEB) May 05, 2015 In ... how important it is for moms to support each other. ... are on each other’s side makes it so much easier. ... make them feel better, feel less alone and help them ... best they can. Moms who are clearly dear friends ...
(Date:5/5/2015)... (PRWEB) May 05, 2015 May is National ... the Institute for Better Bone Health . Founded by ... aims to educate both consumers and physicians about the latest ... of bone health. , According to a study recently published ... total Americans are affected by osteoporosis and low bone mass. ...
(Date:5/5/2015)... (PRWEB) May 05, 2015 After record-breaking ... flavors in 2014, Walgreens introduces the Cookies & Cream ... on innovation, Extend Nutrition has continually raised the bar ... great taste, combined with an unprecedented nutritional profile, backed ... this success, Extend Nutrition will launch additional new products ...
(Date:5/5/2015)... Dealing with injuries and medical expenses following ... Personal injury lawyers are excellent resources for accident victims throughout ... their latest article , the Jones Firm gives the top ... a personal injury lawyer to handle their case. , Working ... waste of time if the lawyer does not have a ...
(Date:5/5/2015)... 2015 The report “Liver ... comparative analysis on the therapeutic development for ... by identifying new targets and MOAs to ... is available at http://www.rnrmarketresearch.com/liver-fibrosis-pipeline-review-h2-2014-market-report.html . ... – Pipeline Review, H2 2014 report include ...
Breaking Medicine News(10 mins):Health News:Just In Time For Mother’s Day, Healthy Birth Day Releases Video Titled “Moms Helping Moms” Encouraging Mothers To Band Together 2Health News:The Institute for Better Bone Health Observes National Osteoporosis Month, Celebrates Three Years of Promoting Healthy Bones 2Health News:The Institute for Better Bone Health Observes National Osteoporosis Month, Celebrates Three Years of Promoting Healthy Bones 3Health News:Nationwide Launch of Extend Nutrition’s Newest Bar Flavors Follows Most Successful New Item Sales in Company History 2Health News:Nationwide Launch of Extend Nutrition’s Newest Bar Flavors Follows Most Successful New Item Sales in Company History 3Health News:Nationwide Launch of Extend Nutrition’s Newest Bar Flavors Follows Most Successful New Item Sales in Company History 4Health News:5 Top Qualifications for Personal Injury Lawyer Disclosed in Latest Article by The Jones Firm 2Health News:Liver Fibrosis Therapeutic Development and Pipeline Market Review H2 2014 Available at RnRMarketResearch.com 2Health News:Liver Fibrosis Therapeutic Development and Pipeline Market Review H2 2014 Available at RnRMarketResearch.com 3
... little difference in chemotherapy treatment; some critics say that,s ... -- A 2003 overhaul of Medicare that changed the ... alter cancer patients, perceptions of their quality of care, ... that cancer patients are waiting the same amount of ...
... Va., Oct. 8 A good night,s sleep,is ... an estimated 70,million Americans complain of sleeplessness. This ... (ACA) is offering,advice to help consumers select comfortable ... and neck pain., "Americans spend one-third of ...
... Ohio to make quality and safety list, AKRON, Ohio, ... named a "Leapfrog Top Hospital" for 2007. The only,facility in ... the nation,to make the list, Summa received this designation based ... a rating system that,assesses hospital quality and safety. According ...
... Oct. 8 Beginning in October, Concentra,("Concentra" or the ... For What Ails,You. This new theme is at the ... centers to various communities in the coming,year, beginning with ... area. The For What Ails You campaign is ...
... Oct. 8, 2007 /PRNewswire-FirstCall/,-- Although rising health ... America,s,local governments, most jurisdictions do not offer ... top health issues, according to,a survey of ... premier local,government leadership and management organization, and ...
... to Hear ... from Top Experts, SAN JOSE, Calif., ... Idiopathic Pulmonary Fibrosis (IPF),is the limitation the disease places on their ability ... that,obstacle for these patients by allowing them to "attend" a seminar,virtually and ...
Cached Medicine News:Health News:Medicare Changes Didn't Alter Cancer Care 2Health News:Medicare Changes Didn't Alter Cancer Care 3Health News:Medicare Changes Didn't Alter Cancer Care 4Health News:Proper Mattress Can Improve Sleep Comfort, Reduce Pain, Says American Chiropractic Association 2Health News:Proper Mattress Can Improve Sleep Comfort, Reduce Pain, Says American Chiropractic Association 3Health News:Summa Health System's Akron City Hospital Named 'Leapfrog Top Hospital' for 2007 2Health News:Concentra Offers a Cure 'For What Ails You' 2Health News:ICMA/CIGNA Survey: U.S. Cities and Counties Begin to Focus on Health Risks and Costs 2Health News:ICMA/CIGNA Survey: U.S. Cities and Counties Begin to Focus on Health Risks and Costs 3Health News:ICMA/CIGNA Survey: U.S. Cities and Counties Begin to Focus on Health Risks and Costs 4Health News:CPF 'Living with IPF' Patient Seminar to be Webcast Live October 13, 2007 2Health News:CPF 'Living with IPF' Patient Seminar to be Webcast Live October 13, 2007 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: